Victory Capital Management
RCUS icon

Victory Capital Management’s Arcus Biosciences RCUS Stock Holding History

Victory Capital Management’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$429K Buy
13,900
+387
+3% +$9.56K ﹤0.01% 2102
2026
Q1 		$292K Buy
13,513
+1,213
+10% +$26.2K ﹤0.01% 2128
2025
Q4 		$293K Buy
12,300
+1,610
+15% +$32.8K ﹤0.01% 2118
2025
Q3 		$145K Sell
10,690
-796
-7% -$8.28K ﹤0.01% 2256
2025
Q2 		$93.5K Sell
11,486
-50,854
-82% -$434K ﹤0.01% 2332
2025
Q1 		$489K Buy
62,340
+16,622
+36% +$193K ﹤0.01% 2038
2024
Q4 		$681K Sell
45,718
-2,764
-6% -$45.1K ﹤0.01% 1947
2024
Q3 		$741K Sell
48,482
-1,220
-2% -$19.2K ﹤0.01% 1894
2024
Q2 		$757K Sell
49,702
-25,624
-34% -$414K ﹤0.01% 1826
2024
Q1 		$1.42M Sell
75,326
-29,087
-28% -$503K ﹤0.01% 1573
2023
Q4 		$1.99M Buy
104,413
+36,312
+53% +$580K ﹤0.01% 1429
2023
Q3 		$1.22M Sell
68,101
-6,062
-8% -$122K ﹤0.01% 1559
2023
Q2 		$1.51M Sell
74,163
-19,903
-21% -$379K ﹤0.01% 1492
2023
Q1 		$1.72M Buy
94,066
+28,403
+43% +$543K ﹤0.01% 1452
2022
Q4 		$1.36M Buy
65,663
+48,003
+272% +$1.32M ﹤0.01% 1581
2022
Q3 		$462K Buy
17,660
+1,898
+12% +$50.2K ﹤0.01% 2082
2022
Q2 		$399K Sell
15,762
-1,469
-9% -$36K ﹤0.01% 2149
2022
Q1 		$417K Buy
17,231
+10,384
+152% +$348K ﹤0.01% 2191
2021
Q4 		$277K Sell
6,847
-436
-6% -$16.9K ﹤0.01% 2404
2021
Q3 		$254K Sell
7,283
-63,577
-90% -$1.98M ﹤0.01% 2438
2021
Q2 		$1.95M Sell
70,860
-1,459,488
-95% -$41.7M ﹤0.01% 1645
2021
Q1 		$43M Buy
1,530,348
+397,786
+35% +$13.8M 0.04% 611
2020
Q4 		$29.4M Sell
1,132,562
-55,997
-5% -$1.36M 0.03% 722
2020
Q3 		$20.4M Buy
1,188,559
+295,955
+33% +$6.61M 0.03% 791
2020
Q2 		$22.1M Buy
892,604
+887,758
+18,319% +$24M 0.03% 732
2020
Q1 		$67K Buy
+4,846
New +$60.3K ﹤0.01% 2433
2019
Q4 		– Sell
-4,491
Closed -$41K – 3131
2019
Q3 		$41K Buy
+4,491
New +$36.1K ﹤0.01% 2769

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Victory Capital Management's RCUS Position: Q2 2026 in Review

Victory Capital Management increased its Arcus Biosciences (RCUS) stake by 2.9% in Q2 2026, buying an estimated $9.56K and bringing the position to 13,900 shares worth $429K. The position accounts for ﹤0.01% of the portfolio, ranked #2102.

Victory Capital Management first reported a position in RCUS in Q3 2019 and has held it in 27 quarters since. The position peaked at $43M in Q1 2021. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Victory Capital Management held 13,900 shares of Arcus Biosciences worth $429K as of Q2 2026.
  • Victory Capital Management bought 387 Arcus Biosciences shares in Q2 2026, an estimated $9.56K.
  • Arcus Biosciences made up ﹤0.01% of Victory Capital Management's portfolio in Q2 2026, its #2102 holding.
  • Victory Capital Management first reported a position in Arcus Biosciences in Q3 2019 and has held it in 27 quarters since.
  • Victory Capital Management's Arcus Biosciences position peaked at $43M in Q1 2021.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.